Core Insights - The 36th Great Wall Cardiology Conference and Asian Heart Congress will take place in Beijing on October 16, 2025, showcasing Huawei's advancements in wearable health technology, particularly in chronic disease management such as blood pressure and atrial fibrillation [1][11] Group 1: Technological Innovations - Huawei's wearable devices are integrating AI for blood pressure management, as demonstrated by a presentation from Professor Chen Yundai, highlighting the results of an AI-enabled wearable device blood pressure follow-up study [2] - The Huawei WATCH GT 6 provides continuous monitoring of atrial fibrillation frequency and duration, offering quantifiable data for stroke prevention, which traditional monitoring methods fail to capture [4] - The advanced technology behind Huawei's devices, including the 70+ detection indicators of the Ascend system, allows for comprehensive health assessments and proactive health management [6] Group 2: Product Development and Clinical Integration - Huawei has developed a closed-loop system for health research, with over 250 health studies and 14 million users contributing to data accumulation, facilitating a seamless transition from data collection to clinical application [7] - The Huawei WATCH D2 has received medical device certifications in multiple countries and features a 24-hour dynamic blood pressure monitoring capability, providing clinical-standard reports for healthcare professionals [9] Group 3: Industry Implications - The aging population presents challenges in cardiovascular disease management, and Huawei's innovations in wearable technology and AI aim to address these issues by extending health monitoring into daily life [11] - The integration of professional medical capabilities into everyday wearable devices positions Huawei's products as a potential first line of defense in family health management, contributing to a broader public health framework [11]